IRIDEX

IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. Its products include lasers, laser delivery and glaucoma devices, retinal surgical instruments, veterinary, and ENT. The company was founded by Eduardo Arias, Theodore A. Boutacoff, David M. Buzawa and James L. Donovan in February 1989 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IRIDEX reports Q1 revenue decline, explores strategic growth opportunities

IRIDEX faces challenges with longer sales cycles and margin pressure but maintains leadership in its core business areas.
Strategic discussions for potential transactions offer growth opportunities for the company and its stockholders.
Addressing revenue decline in retina products and improving cash position are key focus areas for future performance.

IRIDEX reports Q3 mixed results, focuses on cost-cutting and growth

IRIDEX reported mixed financial performance in Q3 2024 with a decline in total revenue but growth in Cyclo G6 product sales.
Efforts to address cash burn through cost-cutting measures and strategic review progress were highlighted.
Challenges in the retina business were noted, but opportunities for improvement in glaucoma products and cost efficiencies were emphasized.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRIDEX Corporation (IRIX) CEO David Bruce on Q1 2020 Results - Earnings Call Transcript

Names Prior CFO/COO as Interim CFO Names Prior CFO/COO as Interim CFO

IRIDEX ANNOUNCES RETIREMENT OF VP FINANCE

IRIDEX Corp (IRIX) CEO David Bruce on Q4 2019 Results - Earnings Call Transcript

IRIDEX Corp (IRIX) CEO David Bruce on Q3 2019 Results - Earnings Call Transcript

Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Iridex (IRIX) Report Negative Earnings Next Week? What You Should Know

MOUNTAIN VIEW, Calif., Oct.  28, 2019  (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the appointment of Robert Gunst as Chairman of the Board, effective October 23, 2019. Concurrent with this appointment, Ruediger Naumann-Etienne departed from the Board of Directors as Lead Independent Director.

IRIDEX Announces Appointment of Robert Gunst as Chairman of the Board of Directors and Departure of Lead Independent Director, Ruediger Naumann-Etienne

MOUNTAIN VIEW, Calif., Sept.  11, 2019  (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that its patented MicroPulse® laser therapy will be featured prominently in research presented at the 2019 European Society of Cataract & Refractive Surgeons (ESCRS) meeting, to be held in Paris, France on Friday, September 13 through Wednesday, September 18. MicroPulse Transscleral Laser Therapy (TLT) is a non-incisional, laser-based procedure used to treat a wide range of glaucoma cases. More than 100,000 procedures have been performed in 60 countries since 2015.

MicroPulse® Transscleral Laser Therapy Will be Discussed in Various Presentations and Educational Events at ESCRS 2019 in Paris, France

Cutera

Lumentum Holdings

Laser Systems & Components Industry Outlook: Prospects Bright

Iridex (IRIX) delivered earnings and revenue surprises of 18.18% and -4.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Iridex (IRIX) Reports Q2 Loss, Lags Revenue Estimates

IRIDEX Corp (IRIX) CEO William Moore on Q1 2019 Results - Earnings Call Transcript

News for IRIDEX Stock (IRIX)